key: cord-0900663-4h5cvvb5
authors: Muntañola, Ana; Villacampa, Guillermo; Hernández-Rivas, José Ángel; Alonso, Rosalía; Mirás, Fátima; Osorio, Santiago; Baile, Mónica; Baltasar, Patricia; López Jiménez, Javier; Hernandez-Rodriguez, Ines; Valenciano, Susana; Alfayate, Ana; Gimeno, Eva; Bárez, Abelardo; Oliveira, Ana C.; Riaza, Rosalía; Romero, Pilar; Delgado, Julio; Yáñez, Lucrecia; Zabalza, Amaya; Torres, Ana; Gómez-Roncero, Mª Isabel; Crespo, Marta; Córdoba, Raúl; Mateos-Mazón, Juan José; Pérez, Sonia; Andreu, Rafael; Labrador, Jorge; Ruiz, Mª Elena; Velasquez, César Andrés; Terol, Mª José; Santiago, Raquel; Vidal, Mª Jesús; Campoy García, Fiz; Villalón, Lucía; Muiña, Begoña S.; Soler, Joan Alfons; Seri, Cristina; Sánchez, Mª José; Cuesta, Amalia; Ramos, Rafael; Sánchez-Montalvá, Adrián; Ruiz-Camps, Isabel; González, Marcos; Abrisqueta, Pau; Bosch, Francesc
title: Clinical characteristics and outcome of SARS-CoV-2 infection in admitted patients with chronic lymphocytic leukemia from a single European country
date: 2020-12-18
journal: Exp Hematol Oncol
DOI: 10.1186/s40164-020-00195-x
sha: 34ebf32859bb4f7f98870458b781ff6a53e09b73
doc_id: 900663
cord_uid: 4h5cvvb5

nan

Spain has been one the most affected countries by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the causative agent of coronavirus disease 2019 (COVID-19) pandemic [1, 2] . Patients with chronic lymphocytic leukemia (CLL) could be at risk of more severe COVID-19 clinical forms [3] since they often carry immune perturbations aggravated by treatments used for the disease itself [4] . Two major series on patients with COVID-19 and CLL encompassing different countries and health systems reported heterogeneous factors related to the outcome [5, 6] . Herein, we are presenting the largest series of CLL patients with proved COVID-19 from a single country and Health system.

We identified 165 patients with CLL and COVID-19 across 40 Spanish centers (Additional file 1: Table S1 and S2) between March 1, 2020 and May 31, 2020. In summary, at the time of infection median age was 73 years, 27% were younger than 65, and 40% had comorbidities (CIRS ≥ 6). Eighty-five patients (52%) were in watch & wait (W&W), 34 (21%) had been previously treated, whereas 46 patients (28%) were currently on CLL treatment, mainly with BTK inhibitors (BTKi) (n = 34) and venetoclax (n = 7). Increased CRP (> 0.3 mg/dL) was detected in 27.8%, increased D-dimer (> 500 mg/mL) in 70%, ferritin > 400 mg/mL in 74%, and elevated IL-6 in 88% of patients in whom it was assessed. Among these inflammatory parameters, ferritin and D-dimer were significantly lower in patients receiving BTKi at the time of COVID-19 compared to the others (Additional file 1: Fig.  S1 ). 92% of the patients required hospital admission, with 31% requiring intensive management.

Regarding survival, 45 deaths (27%) were observed, all of them due to SARS-CoV-2 infection. The case fatality Fig. 1d ). Mortality rate by segments of age was contrasted with 937 patients admitted for COVID-19 at University Hospital Vall d'Hebron, excluding patients with hematologic malignancies, solid tumors, or with other causes of immunosuppression. Overall, mortality rates were higher in CLL patients (adjusted OR = 1.74 [95% CI 1.14-2.65], p = 0.01). The major difference between both cohorts was observed in the higher mortality for CLL patients < 60 years (16.7% vs 0.7%, p < 0.001). Of note, three out of the four young CLL patients that died were untreated and lack comorbidities, suggesting a negative effect of CLL in those patients. Finally, mortality was significantly higher compared to the mortality rates by age reported by the Spanish Ministry of Health up to May 2020 (adjusted OR = 3.91 [95% CI 2.70-5.66], p < 0.001) ( Fig. 2 and Additional file 1: Table S4 ).

The inferior survival observed in patients with CLL and COVID-19 in our series seems to be similar to the data reported in other series of patients with hematologic malignancies, pointing to a patient population more vulnerable to COVID-19 infection [7] .

In summary, in our series mortality rate was 27%, with a CFR for admitted patients of 33.6%, resembling the ones reported by Mato et al. [5] and by the ERIC/ CLL Campus series [6] . In contrast to the observations reported by the ERIC/CLL Campus series, and in agreement with Mato et al. [5] , age and comorbidities were strongly related to mortality. Importantly, and as opposed to the two former mentioned series [5, 6] , lymphocytosis was associated with OS, suggesting that a more active CLL disease at the time of infection could increase the vulnerability to COVID-19. The inflammatory parameters analyzed in our series corelated with COVID-19 outcome. Thus, increased CRP and D-dimer predicted for a shorter survival, the latter maintaining its adverse prognostic impact in the multivariate analysis. Finally, in our series and in agreement with Mato et al. [5] patients receiving BTKi at the time of COVID-19 presented similar outcome as patients never treated and, accordingly exhibit lower levels of ferritin and D-dimer, which could be in part explained by the suggested protective role of BTKi against SARS-CoV-2 infection severity due to its immune-modulator effect [8] [9] [10] .

10 Hospital Universitario Ramón y Cajal

24 Department of Hematology, Vall d'Hebron Barcelona Hospital Campus, Passeig de la Vall d'Hebron

32 Hospital Clínico Universitario de Valencia

39 Hospital Central de la Defensa Gómez Ulla

Clinical characteristics of coronavirus disease 2019 in China

Chronic lymphocytic leukemia management in Italy during the COVID-19 pandemic: a Campus CLL report

Perturbation of the normal immune system in patients with CLL

Outcomes of COVID-19 in patients with CLL: a multicenter, international experience

COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by

Mortality rates in different groups of age comparing admitted patients with CLL to (a) patients admitted at University Hospital Vall d'Hebron Campus

37 • fast, convenient online submission • thorough peer review by experienced researchers in your field • rapid publication on acceptance • support for research data, including large and complex data types • gold Open Access which fosters wider collaboration and increased citations maximum visibility for your research: over 100M website views per year research ? Choose BMC

Research Initiative on CLL, and CLL Campus. Leukemia

Clinical portrait of the SARS-CoV-2 epidemic in European patients with cancer

The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19-infected patients

Protective role of Bruton tyrosine kinase inhibitors in patients with chronic lymphocytic leukaemia and COVID-19

Inhibition of Bruton tyrosine kinase in patients with severe COVID-19

Publisher's Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations

The online version contains supplementary material available at https ://doi. org/10.1186/s4016 4-020-00195 -x.Additional file 1: Table S1 . Patient and CLL features at the time of COVID-19 infection (n = 165). Table S2 . COVID-19 manifestations, management, and outcomes. Table S3 . Univariate and multivariate OS analysis of baseline characteristics. Table S4 . Characteristics of patients infected by SARS-CoV-2 i) treated at University Hospital Vall d'Hebron and ii) overall Spanish population. Figure S1 . Levels of inflammatory parameters according to treatment with BTKi. (* indicates p < 0.05).

All authors read and approved the final manuscript.

The authors declares no competing interest.